

PHARMACEUTICAL 2023

Rain Oncology Inc. Rank 152 of 446







Rain Oncology Inc. Rank 152 of 446

The relative strengths and weaknesses of Rain Oncology Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Rain Oncology Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 105% points. The greatest weakness of Rain Oncology Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 37% points.

The company's Economic Capital Ratio, given in the ranking table, is 151%, being 108% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	133,628
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	21,966
Liabilities, Non-Current	178
Other Assets	1,459
Other Compr. Net Income	-77
Other Expenses	3.0
Other Liabilities	0
Other Net Income	1,415
Other Revenues	0
Property and Equipment	93
Research and Development	61,400
Selling, General and Administrative Expense	15,736

Output Variable	Value in 1000 USD
Assets	135,180
Liabilities	22,144
Expenses	77,139
Revenues	0
Stockholders Equity	113,036
Net Income	-75,724
Comprehensive Net Income	-75,762
Economic Capital Ratio	151%

